{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:20:28Z","timestamp":1789147228625,"version":"build-2803163510"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001747","name":"Hong Kong Baptist University","doi-asserted-by":"publisher","award":["SDF 19- 1216-P03"],"award-info":[{"award-number":["SDF 19- 1216-P03"]}],"id":[{"id":"10.13039\/501100001747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["12101023"],"award-info":[{"award-number":["12101023"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma multiforme (GBM) is a lethal brain tumor. With the current gold standard chemotherapy treatment, temozolomide (TMZ), many patients do not survive beyond one year. While the urgency of researching novel treatments is understandable, the prohibitively high costs and the prolonged duration of research and clinical trials significantly delay the availability of medical advancements to the general public. This highlights the urgent need for adjuvant therapies to enhance treatment effectiveness.<\/jats:p>\n                    <jats:p>Main body: Recent research has suggested the potential of repurposing FDA-approved drugs such as temozolomide (TMZ), disulfiram (DSF), and aspirin for the treatment of glioblastoma, with encouraging evidence particularly for DSF and aspirin. Additionally, compounds like histone deacetylase inhibitors (e.g., vorinostat) are being investigated for their impact on non-coding RNA (ncRNA) modulation, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Combining traditional therapies with ncRNA modulation has shown potential in enhancing therapeutic efficacy and targeting specificity. NcRNAs play a crucial role in regulating gene expression and have been implicated in tumor growth, invasion, and treatment resistance. Recent discoveries, such as cuproptosis, offer new insights into tumor cell death mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review focuses on how these molecular insights can serve as novel therapeutic targets and how drug adjuvant therapy may improve GBM treatment strategies. It focuses on how the integration of ncRNA modulation with conventional therapies and the combination strategy of enhancing efficacy of drugs can enhance treatment efficacy and pave the way for innovative approaches in managing GBM. In short, we will explore how non-coding RNAs (ncRNAs) might serve as promising targets and how repurposing TMZ, DSF, and aspirin could help enhance the efficacy of GBM treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-025-01900-5","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T01:18:28Z","timestamp":1750468708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches"],"prefix":"10.1186","volume":"17","author":[{"given":"Meijun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Chat Pan","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"1","key":"1900_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40478-023-01605-x","volume":"11","author":"F Ah-Pine","year":"2023","unstructured":"Ah-Pine F, Khettab M, Bedoui Y, Slama Y, Daniel M, Doray B, Gasque P. On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells. Acta Neuropathol Commun. 2023;11(1):104.","journal-title":"Acta Neuropathol Commun"},{"key":"1900_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol. 2015;17:iv1\u201362.","journal-title":"Neuro Oncol"},{"key":"1900_CR3","doi-asserted-by":"crossref","unstructured":"Wirsching HG, Weller M. Glioblastoma. Malig Brain Tumors State-of-the-Art Treat. 2017;265\u2013288.","DOI":"10.1007\/978-3-319-49864-5_18"},{"issue":"4","key":"1900_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA A Cancer J Clin. 2020;70(4):299\u2013312.","journal-title":"CA A Cancer J Clin"},{"issue":"1","key":"1900_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1[J]. Cancer Cell. 2010;17(1):98\u2013110.","journal-title":"Cancer Cell"},{"issue":"1","key":"1900_CR6","doi-asserted-by":"publisher","first-page":"vdab144","DOI":"10.1093\/noajnl\/vdab144","volume":"3","author":"Y Tang","year":"2021","unstructured":"Tang Y, Qazi MA, Brown KR, Mikolajewicz N, Moffat J, Singh SK, McNicholas PD. Identification of five important genes to predict glioblastoma subtypes. Neuro-Oncol Adv. 2021;3(1):vdab144.","journal-title":"Neuro-Oncol Adv"},{"key":"1900_CR7","doi-asserted-by":"crossref","unstructured":"Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, DeCarvalho AC, Lyu S, Li P, Li Y. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42\u201356. e46.","DOI":"10.1016\/j.ccell.2017.06.003"},{"key":"1900_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.thromres.2018.05.001","volume":"167","author":"S Lehrer","year":"2018","unstructured":"Lehrer S, Dembitzer FR, Rheinstein PH, Rosenzweig KE. In primary glioblastoma fewer tumor copy number segments of the F13A1 gene are associated with poorer survival. Thromb Res. 2018;167:12\u20134.","journal-title":"Thromb Res"},{"issue":"1","key":"1900_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41(1):142.","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"1900_CR10","doi-asserted-by":"publisher","first-page":"22047","DOI":"10.1002\/cam4.6789","volume":"12","author":"D Feucht","year":"2023","unstructured":"Feucht D, Kerscher SR, Ruff C, Schuhmann MU, Roder C, Zipfel J. Retrospective longitudinal assessment of optic nerve sheath diameter in patients with malignant glioma. Cancer Med. 2023;12(24):22047\u201355.","journal-title":"Cancer Med"},{"key":"1900_CR11","doi-asserted-by":"crossref","unstructured":"Fekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology meets bioengineering: improving the effectiveness of glioblastoma immunotherapy. Cancers (Basel). 2022;14(15).","DOI":"10.3390\/cancers14153698"},{"issue":"4","key":"1900_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299\u2013312.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"1900_CR13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1200\/JCO.2017.73.0119","volume":"35","author":"BM Alexander","year":"2017","unstructured":"Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1900_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","volume":"39","author":"M Schlander","year":"2021","unstructured":"Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. How much does it cost to research and develop a new drug? A systematic review and assessment. Pharmacoeconomics. 2021;39(11):1243\u201369.","journal-title":"Pharmacoeconomics"},{"issue":"10149","key":"1900_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","volume":"392","author":"L Luzzatto","year":"2018","unstructured":"Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, K\u00e4\u00e4ri\u00e4inen H, Garattini S, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791\u20134.","journal-title":"Lancet"},{"issue":"1","key":"1900_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"1900_CR17","doi-asserted-by":"crossref","unstructured":"Ntafoulis I, Koolen SLW, Leenstra S, Lamfers MLM. Drug repurposing, a fast-track approach to develop effective treatments for glioblastoma. Cancers (Basel). 2022;14(15).","DOI":"10.3390\/cancers14153705"},{"issue":"1","key":"1900_CR18","doi-asserted-by":"publisher","first-page":"18332","DOI":"10.1038\/s41598-022-22822-9","volume":"12","author":"S Ghiam","year":"2022","unstructured":"Ghiam S, Eslahchi C, Shahpasand K, Habibi-Rezaei M, Gharaghani S. Identification of repurposed drugs targeting significant long non-coding RNAs in the cross-talk between diabetes mellitus and Alzheimer\u2019s disease. Sci Rep. 2022;12(1):18332.","journal-title":"Sci Rep"},{"issue":"12","key":"1900_CR19","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/genes12122005","volume":"12","author":"LD Nguyen","year":"2021","unstructured":"Nguyen LD, Chau RK, Krichevsky AM. Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer\u2019s disease and related dementias. Genes. 2021;12(12):2005.","journal-title":"Genes"},{"key":"1900_CR20","doi-asserted-by":"crossref","unstructured":"Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackerm\u00fcller Jr, Hofacker IL. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316(5830):1484\u20131488.","DOI":"10.1126\/science.1138341"},{"issue":"1","key":"1900_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers11010017","volume":"11","author":"R Rynkeviciene","year":"2018","unstructured":"Rynkeviciene R, Simiene J, Strainiene E, Stankevicius V, Usinskiene J, Kaubriene EM, Meskinyte I, Cicenas J, Suziedelis K. Non-coding RNAs in glioma. Cancers. 2018;11(1):17. https:\/\/doi.org\/10.3390\/cancers11010017.","journal-title":"Cancers"},{"key":"1900_CR22","doi-asserted-by":"crossref","unstructured":"DiStefano JK. The emerging role of long noncoding RNAs in human disease. Dis Gene Identif Methods Protoc. 2018;91\u2013110.","DOI":"10.1007\/978-1-4939-7471-9_6"},{"issue":"1","key":"1900_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diff.2009.04.002","volume":"78","author":"LA Mathews","year":"2009","unstructured":"Mathews LA, Crea F, Farrar W. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation. 2009;78(1):1\u201317.","journal-title":"Differentiation"},{"key":"1900_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0065-2660(07)00009-0","volume":"61","author":"E Ballestar","year":"2008","unstructured":"Ballestar E, Esteller M. Epigenetic gene regulation in cancer. Adv Genet. 2008;61:247\u201367.","journal-title":"Adv Genet"},{"issue":"1","key":"1900_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1369\/0022155413506582","volume":"62","author":"S Parbin","year":"2014","unstructured":"Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem. 2014;62(1):11\u201333.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"1900_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","volume":"15","author":"I Oehme","year":"2009","unstructured":"Oehme I, Deubzer HE, Wegener D, Pickert D, Linke J-P, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, Von Deimling A. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009;15(1):91\u20139.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1900_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5(10):981\u20139.","journal-title":"Mol Cancer Res"},{"key":"1900_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fphar.2020.00537","volume":"11","author":"S Shukla","year":"2020","unstructured":"Shukla S, Tekwani BL. Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Front Pharmacol. 2020;11:537.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1900_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","volume":"31","author":"P Bezecny","year":"2014","unstructured":"Bezecny P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med Oncol. 2014;31(6):985.","journal-title":"Med Oncol"},{"issue":"10","key":"1900_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"1900_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","volume":"338","author":"I Gregoretti","year":"2004","unstructured":"Gregoretti I, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17\u201331.","journal-title":"J Mol Biol"},{"issue":"3","key":"1900_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1073\/pnas.0408732102","volume":"102","author":"J Ungerstedt","year":"2005","unstructured":"Ungerstedt J, Sowa Y, Xu W-S, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks P. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci. 2005;102(3):673\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"1900_CR33","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27(12):2052\u20138.","journal-title":"J Clin Oncol"},{"key":"1900_CR34","doi-asserted-by":"publisher","first-page":"120024","DOI":"10.1016\/j.lfs.2021.120024","volume":"286","author":"JR Mekala","year":"2021","unstructured":"Mekala JR, Kurappalli RK, Ramalingam P, Moparthi NR. N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro. Life Sci. 2021;286:120024.","journal-title":"Life Sci"},{"key":"1900_CR35","doi-asserted-by":"crossref","unstructured":"Obrador E, Moreno-Murciano P, Oriol-Caballo M, L\u00f3pez-Blanch R, Pineda B, Guti\u00e9rrez-Arroyo JL, Loras A, Gonzalez-Bonet LG, Martinez-Cadenas C, Estrela JM et al. Glioblastoma therapy: past, present and future. Int J Mol Sci. 2024;25(5).","DOI":"10.3390\/ijms25052529"},{"issue":"3","key":"1900_CR36","doi-asserted-by":"publisher","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","volume":"4","author":"FL Ricklefs","year":"2018","unstructured":"Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018;4(3):eaar2766.","journal-title":"Sci Adv"},{"issue":"7","key":"1900_CR37","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/neuonc\/noaa029","volume":"22","author":"BT Himes","year":"2020","unstructured":"Himes BT, Peterson TE, de Mooij T, Garcia LMC, Jung MY, Uhm S, Yan D, Tyson J, Jin-Lee HJ, Parney D, et al. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro Oncol. 2020;22(7):967\u201378.","journal-title":"Neuro Oncol"},{"issue":"10","key":"1900_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/jnnp-2020-325334","volume":"92","author":"R Ma","year":"2021","unstructured":"Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry. 2021;92(10):1103\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1900_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.bbrc.2005.07.030","volume":"334","author":"SA Ciafr\u00e8","year":"2005","unstructured":"Ciafr\u00e8 SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334(4):1351\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"1900_CR40","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cam4.775","volume":"5","author":"A Shea","year":"2016","unstructured":"Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, et al. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016;5(8):1917\u201346.","journal-title":"Cancer Med"},{"issue":"17","key":"1900_CR41","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.18632\/oncotarget.28039","volume":"12","author":"M Chen","year":"2021","unstructured":"Chen M, Medarova Z, Moore A. Role of microRNAs in glioblastoma. Oncotarget. 2021;12(17):1707\u201323.","journal-title":"Oncotarget"},{"issue":"4","key":"1900_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.32604\/or.2023.029062","volume":"31","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang Y, Gao H, Li X, Li P. Underlying mechanisms and clinical potential of circRNAs in glioblastoma. Oncol Res. 2023;31(4):449\u201362.","journal-title":"Oncol Res"},{"issue":"1","key":"1900_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/mc.22739","volume":"57","author":"J Shen","year":"2018","unstructured":"Shen J, Hodges TR, Song R, Gong Y, Calin GA, Heimberger AB, Zhao H. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018;57(1):137\u201341.","journal-title":"Mol Carcinog"},{"issue":"4","key":"1900_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31083\/j.jin2104111","volume":"21","author":"AM Eraky","year":"2022","unstructured":"Eraky AM, Keles A, Goodman SL, Baskaya MK. Serum long non-coding RNAs as potential noninvasive biomarkers for glioblastoma diagnosis, prognosis, and chemoresistance. J Integr Neurosci. 2022;21(4):111.","journal-title":"J Integr Neurosci"},{"key":"1900_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semcancer.2020.12.015","volume":"83","author":"MS Uddin","year":"2022","unstructured":"Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, Ashraf GM. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. Semin Cancer Biol. 2022;83:100\u201320.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"1900_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/onc.2016.199","volume":"36","author":"YK Banasavadi-Siddegowda","year":"2017","unstructured":"Banasavadi-Siddegowda YK, Russell L, Frair E, Karkhanis VA, Relation T, Yoo JY, Zhang J, Sif S, Imitola J, Baiocchi R, et al. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene. 2017;36(2):263\u201374.","journal-title":"Oncogene"},{"issue":"4","key":"1900_CR47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/EBC20200032","volume":"65","author":"H Yan","year":"2021","unstructured":"Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65(4):625\u201339.","journal-title":"Essays Biochem"},{"key":"1900_CR48","doi-asserted-by":"crossref","unstructured":"DeOcesano-Pereira C, Machado RAC, Chudzinski-Tavassi AM, Sogayar MC. Emerging roles and potential applications of non-coding RNAs in glioblastoma. Int J Mol Sci. 2020;21(7).","DOI":"10.3390\/ijms21072611"},{"issue":"11","key":"1900_CR49","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s11010-021-04221-2","volume":"476","author":"A Movahedpour","year":"2021","unstructured":"Movahedpour A, Khatami SH, Khorsand M, Salehi M, Savardashtaki A, Mirmajidi SH, Negahdari B, Khanjani N, Naeli P, Vakili O, et al. Exosomal noncoding RNAs: key players in glioblastoma drug resistance. Mol Cell Biochem. 2021;476(11):4081\u201392.","journal-title":"Mol Cell Biochem"},{"key":"1900_CR50","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fonc.2019.00485","volume":"9","author":"Z Yang","year":"2019","unstructured":"Yang Z, Wei D, Dai X, Stevens MFG, Bradshaw TD, Luo Y, Zhang J. C8-substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage. Front Oncol. 2019;9:485.","journal-title":"Front Oncol"},{"key":"1900_CR51","doi-asserted-by":"publisher","first-page":"105890","DOI":"10.1016\/j.clineuro.2020.105890","volume":"196","author":"Y Wang","year":"2020","unstructured":"Wang Y, Feng Y. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: a meta-analysis of randomized controlled studies. Clin Neurol Neurosurg. 2020;196:105890.","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"1900_CR52","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.1021\/acs.cgd.2c00866","volume":"22","author":"H Yu","year":"2022","unstructured":"Yu H, Zhang B, Xing W, Liu M, Yang D, He G, Wang F, Zhang L, Gong N, Lu Y, et al. Five cocrystal forms of antitumor drug temozolomide with p-hydroxybenzoic acid: structure, computational analysis, characterizations, stability, and transformation. Cryst Growth Des. 2022;22(12):7195\u2013206.","journal-title":"Cryst Growth Des"},{"issue":"6","key":"1900_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4196\/kjpp.2019.23.6.475","volume":"23","author":"W Shangguan","year":"2019","unstructured":"Shangguan W, Lv X, Tian N. FoxD2-AS1 is a prognostic factor in glioma and promotes temozolomide resistance in a O(6)-methylguanine-DNA methyltransferase-dependent manner. Korean J Physiol Pharmacol. 2019;23(6):475\u201382.","journal-title":"Korean J Physiol Pharmacol"},{"issue":"D1","key":"1900_CR54","doi-asserted-by":"publisher","first-page":"D831","DOI":"10.1093\/nar\/gkaa793","volume":"49","author":"FB Bastian","year":"2021","unstructured":"Bastian FB, Roux J, Niknejad A, Comte A, Fonseca SS, de Costa TM, Farias S, Moretti G, de Parmentier VR, Laval MR, et al. The Bgee suite: integrated curated expression atlas and comparative transcriptomics in animals. Nucl Acids Res. 2021;49(D1):D831\u201347.","journal-title":"Nucl Acids Res"},{"key":"1900_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.humpath.2022.02.016","volume":"123","author":"M Cheng","year":"2022","unstructured":"Cheng M, Wang Q, Chen L, Zhao D, Tang J, Xu J, He Z. LncRNA UCA1\/miR-182-5p\/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways. Hum Pathol. 2022;123:59\u201373.","journal-title":"Hum Pathol"},{"issue":"1","key":"1900_CR56","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1038\/s41467-019-10025-2","volume":"10","author":"P Wu","year":"2019","unstructured":"Wu P, Cai J, Chen Q, Han B, Meng X, Li Y, Li Z, Wang R, Lin L, Duan C, et al. Lnc-TALC promotes O(6)-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun. 2019;10(1):2045.","journal-title":"Nat Commun"},{"issue":"3","key":"1900_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1152\/physiolgenomics.00208.2006","volume":"28","author":"WS Liang","year":"2007","unstructured":"Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, Caselli RJ, Kukull WA, McKeel D, Morris JC, et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics. 2007;28(3):311\u201322.","journal-title":"Physiol Genomics"},{"issue":"40","key":"1900_CR58","doi-asserted-by":"publisher","first-page":"15605","DOI":"10.1073\/pnas.0806883105","volume":"105","author":"NC Berchtold","year":"2008","unstructured":"Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, Beach T, Miller C, Troncoso J, Trojanowski JQ, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A. 2008;105(40):15605\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1900_CR59","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/bio.2015.0032","volume":"13","author":"LJ Carithers","year":"2015","unstructured":"Carithers LJ, Ardlie K, Barcus M, Branton PA, Britton A, Buia SA, Compton CC, DeLuca DS, Peter-Demchok J, Gelfand ET, et al. A novel approach to high-quality postmortem tissue procurement: the GTEx Project. Biopreserv Biobank. 2015;13(5):311\u20139.","journal-title":"Biopreserv Biobank"},{"issue":"4","key":"1900_CR60","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41587-019-0055-9","volume":"37","author":"J Zhang","year":"2019","unstructured":"Zhang J, Bajari R, Andric D, Gerthoffert F, Lepsa A, Nahal-Bose H, Stein LD, Ferretti V. The international cancer genome consortium data portal. Nat Biotechnol. 2019;37(4):367\u20139.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"1900_CR61","doi-asserted-by":"publisher","first-page":"14843","DOI":"10.18632\/aging.203182","volume":"13","author":"G Mazor","year":"2021","unstructured":"Mazor G, Smirnov D, David HB, Khrameeva E, Toiber D, Rotblat B. TP73-AS1 is induced by YY1 during TMZ treatment and highly expressed in the aging brain. Aging. 2021;13(11):14843\u201361. https:\/\/doi.org\/10.18632\/aging.203182.","journal-title":"Aging"},{"issue":"1","key":"1900_CR62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-018-0618-0","volume":"11","author":"H Li","year":"2018","unstructured":"Li H, Chen L, Li JJ, Zhou Q, Huang A, Liu WW, Wang K, Gao L, Qi ST, Lu YT. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3\/Bcl2 signaling pathway. J Hematol Oncol. 2018;11(1):70.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"1900_CR63","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1080\/15384101.2015.1093711","volume":"14","author":"FM Kouri","year":"2015","unstructured":"Kouri FM, Ritner C, Stegh AH. miRNA-182 and the regulation of the glioblastoma phenotype\u2014toward miRNA-based precision therapeutics. Cell Cycle. 2015;14(24):3794\u2013800.","journal-title":"Cell Cycle"},{"issue":"11","key":"1900_CR64","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24(11):1935\u201349.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1900_CR65","doi-asserted-by":"publisher","first-page":"e2253285","DOI":"10.1001\/jamanetworkopen.2022.53285","volume":"6","author":"C Guo","year":"2023","unstructured":"Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, Li J, Sai K, Xi S, Ouyang H, et al. Adjuvant temozolomide chemotherapy with or without interferon Alfa among patients with newly diagnosed high-grade gliomas: a randomized clinical trial. JAMA Netw Open. 2023;6(1):e2253285\u2013e2253285.","journal-title":"JAMA Netw Open"},{"issue":"13","key":"1900_CR66","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cancers16132397","volume":"16","author":"L Magrassi","year":"2024","unstructured":"Magrassi L, Pinton G, Luzzi S, Comincini S, Scravaglieri A, Gigliotti V, Bernardoni BL, D\u2019Agostino I, Juretich F, La Motta C, et al. A new vista of aldehyde dehydrogenase 1A3 (ALDH1A3): new specific inhibitors and activity-based probes targeting ALDH1A3 dependent pathways in glioblastoma, mesothelioma and other cancers. Cancers. 2024;16(13):2397.","journal-title":"Cancers"},{"issue":"4","key":"1900_CR67","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41418-023-01125-0","volume":"30","author":"C Xiong","year":"2023","unstructured":"Xiong C, Ling H, Hao Q, Zhou X. Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ. 2023;30(4):876\u201384.","journal-title":"Cell Death Differ"},{"issue":"11","key":"1900_CR68","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482\u201390.","journal-title":"Clin Cancer Res"},{"key":"1900_CR69","doi-asserted-by":"crossref","unstructured":"van Noorden CJF, Hira VVV, van Dijck AJ, Novak M, Breznik B, Molenaar RJ. Energy metabolism in IDH1 wild-type and IDH1-mutated glioblastoma stem cells: A Novel Target for Therapy?. Cells. 2021;10(3).","DOI":"10.3390\/cells10030705"},{"issue":"12","key":"1900_CR70","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/CM9.0000000000002909","volume":"137","author":"M Zeng","year":"2024","unstructured":"Zeng M, Wu B, Wei W, Jiang Z, Li P, Quan Y, Hu X. Disulfiram: a novel repurposed drug for cancer therapy. Chin Med J (Engl). 2024;137(12):1389\u201398.","journal-title":"Chin Med J (Engl)"},{"key":"1900_CR71","doi-asserted-by":"publisher","first-page":"683695","DOI":"10.3389\/fonc.2021.683695","volume":"11","author":"Y Xu","year":"2021","unstructured":"Xu Y, Lu L, Luo J, Wang L, Zhang Q, Cao J, Jiao Y. Disulfiram alone functions as a radiosensitizer for pancreatic cancer both in vitro and in vivo. Front Oncol. 2021;11:683695.","journal-title":"Front Oncol"},{"issue":"7","key":"1900_CR72","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1541-7786.MCR-18-0042","volume":"16","author":"X Yun","year":"2018","unstructured":"Yun X, Zhang K, Wang J, Pangeni RP, Yang L, Bonner M, Wu J, Wang J, Nardi IK, Gao M, et al. Targeting USP22 suppresses tumorigenicity and enhances cisplatin sensitivity through ALDH1A3 downregulation in cancer-initiating cells from lung adenocarcinoma. Mol Cancer Res. 2018;16(7):1161\u201371.","journal-title":"Mol Cancer Res"},{"key":"1900_CR73","doi-asserted-by":"publisher","first-page":"109371","DOI":"10.1016\/j.biopha.2019.109371","volume":"118","author":"F Guo","year":"2019","unstructured":"Guo F, Yang Z, Kulbe H, Albers AE, Sehouli J, Kaufmann AM. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by disulfiram and copper treatment through ALDH and ROS modulation. Biomed Pharmacother. 2019;118:109371.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"1900_CR74","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/bjc.2012.442","volume":"107","author":"P Liu","year":"2012","unstructured":"Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, et al. Cytotoxic effect of disulfiram\/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107(9):1488\u201397.","journal-title":"Br J Cancer"},{"key":"1900_CR75","doi-asserted-by":"publisher","first-page":"120250","DOI":"10.1016\/j.ijpharm.2021.120250","volume":"597","author":"Y Qu","year":"2021","unstructured":"Qu Y, Li A, Ma L, Iqbal S, Sun X, Ma W, Li C, Zheng D, Xu Z, Zhao Z, et al. Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. Int J Pharm. 2021;597:120250.","journal-title":"Int J Pharm"},{"issue":"1","key":"1900_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11060-018-2775-y","volume":"138","author":"J Huang","year":"2018","unstructured":"Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC, Kim AH. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. J Neurooncol. 2018;138(1):105\u201311.","journal-title":"J Neurooncol"},{"issue":"3","key":"1900_CR77","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11060-019-03125-y","volume":"142","author":"J Huang","year":"2019","unstructured":"Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S, Campian JL. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol. 2019;142(3):537\u201344.","journal-title":"J Neurooncol"},{"key":"1900_CR78","doi-asserted-by":"crossref","unstructured":"Huang J, Campian JL, DeWees TA, Skrott Z, Mistrik M, Johanns TM, Ansstas G, Butt O, Leuthardt E, Dunn GP et al. A phase 1\/2 study of disulfiram and copper with concurrent radiation therapy and temozolomide for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2024.","DOI":"10.1016\/j.ijrobp.2024.05.009"},{"issue":"3","key":"1900_CR79","doi-asserted-by":"publisher","first-page":"e234149","DOI":"10.1001\/jamanetworkopen.2023.4149","volume":"6","author":"K Werlenius","year":"2023","unstructured":"Werlenius K, Kinhult S, Solheim TS, Magelssen H, L\u00f6fgren D, Mudaisi M, Hylin S, Bartek J Jr, Strand\u00e9us M, Lindskog M, et al. Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: a randomized clinical trial. JAMA Netw Open. 2023;6(3):e234149.","journal-title":"JAMA Netw Open"},{"issue":"6586","key":"1900_CR80","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"issue":"1","key":"1900_CR81","doi-asserted-by":"publisher","first-page":"22323","DOI":"10.1038\/s41598-024-72664-w","volume":"14","author":"S Hao","year":"2024","unstructured":"Hao S, Gao M, Li Q, Shu L, Wang P, Hao G. Machine learning predicts cuproptosis-related lncRNAs and survival in glioma patients. Sci Rep. 2024;14(1):22323.","journal-title":"Sci Rep"},{"key":"1900_CR82","unstructured":"Kaler SG, DiStasio AT. ATP7A-Related copper transport disorders, In: Adam MP, Feldman J, Mirzaa GM \u7b49. (eds) GeneReviews. National Center for Biotechnology Information, Seattle (WA). 1993."},{"issue":"12","key":"1900_CR83","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1002\/1878-0261.13079","volume":"15","author":"W Gao","year":"2021","unstructured":"Gao W, Huang Z, Duan J, Nice EC, Lin J, Huang C. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. Mol Oncol. 2021;15(12):3527\u201344.","journal-title":"Mol Oncol"},{"issue":"3","key":"1900_CR84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1615\/JEnvironPatholToxicolOncol.2023047159","volume":"42","author":"J Jin","year":"2023","unstructured":"Jin J, Li R, Guo G, Chen Y, Li ZA, Zheng J. Studies on the therapeutic and prognostic biomarkers of glioma using a novel cuproptosis-related IncRNA signature and validation in glioma. J Environ Pathol Toxicol Oncol. 2023;42(3):53\u201370.","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"1","key":"1900_CR85","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ng0193-14","volume":"3","author":"J Chelly","year":"1993","unstructured":"Chelly J, T\u00fcmer Z, T\u00f8nnesen T, Petterson A, Ishikawa-Brush Y, Tommerup N, Horn N, Monaco AP. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet. 1993;3(1):14\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"1900_CR86","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ng0193-7","volume":"3","author":"C Vulpe","year":"1993","unstructured":"Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet. 1993;3(1):7\u201313.","journal-title":"Nat Genet"},{"issue":"6","key":"1900_CR87","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1158\/1535-7163.MCT-23-0876","volume":"23","author":"L Song","year":"2024","unstructured":"Song L, Nguyen V, Xie J, Jia S, Chang CJ, Uchio E, Zi X. ATPase copper transporting beta (ATP7B) Is a novel target for improving the therapeutic efficacy of docetaxel by disulfiram\/copper in human prostate cancer. Mol Cancer Ther. 2024;23(6):854\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1900_CR88","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12885-023-10714-8","volume":"23","author":"M Zhang","year":"2023","unstructured":"Zhang M, Liu X, Wang D, Ruan X, Wang P, Liu L, Xue Y. A novel cuproptosis-related gene signature to predict prognosis in Glioma. BMC Cancer. 2023;23(1):237.","journal-title":"BMC Cancer"},{"key":"1900_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2018.02.039","volume":"827","author":"X Wu","year":"2018","unstructured":"Wu X, Xue X, Wang L, Wang W, Han J, Sun X, Zhang H, Liu Y, Che X, Yang J, et al. Suppressing autophagy enhances disulfiram\/copper-induced apoptosis in non-small cell lung cancer. Eur J Pharmacol. 2018;827:1\u201312.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"1900_CR90","doi-asserted-by":"publisher","first-page":"e0236119","DOI":"10.1371\/journal.pone.0236119","volume":"15","author":"H Yoshino","year":"2020","unstructured":"Yoshino H, Yamada Y, Enokida H, Osako Y, Tsuruda M, Kuroshima K, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma[J]. PLoS ONE. 2020;15(7):e0236119.","journal-title":"PLoS ONE"},{"issue":"1","key":"1900_CR91","doi-asserted-by":"publisher","first-page":"11325","DOI":"10.1038\/s41598-022-15251-1","volume":"12","author":"G Zhang","year":"2022","unstructured":"Zhang G, Sun J, Zhang X. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma. Sci Rep. 2022;12(1):11325.","journal-title":"Sci Rep"},{"issue":"1","key":"1900_CR92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12957-022-02727-7","volume":"20","author":"F Wang","year":"2022","unstructured":"Wang F, Lin H, Su Q, Li C. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. World J Surg Oncol. 2022;20(1):275.","journal-title":"World J Surg Oncol"},{"issue":"7\u20138","key":"1900_CR93","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s10495-023-01843-3","volume":"28","author":"HF Yao","year":"2023","unstructured":"Yao HF, Xu DP, Zheng JH, Xu Y, Jia QY, Zhu YH, Yang J, He RZ, Ma D, Yang MW, et al. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Apoptosis. 2023;28(7\u20138):1090\u2013112.","journal-title":"Apoptosis"},{"issue":"2","key":"1900_CR94","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ihj.2019.04.001","volume":"71","author":"AK Singal","year":"2019","unstructured":"Singal AK, Karthikeyan G. Aspirin for primary prevention: Is this the end of the road? Indian Heart J. 2019;71(2):113\u20137.","journal-title":"Indian Heart J"},{"issue":"9","key":"1900_CR95","doi-asserted-by":"publisher","first-page":"220124","DOI":"10.1098\/rsob.220124","volume":"12","author":"P Elwood","year":"2022","unstructured":"Elwood P, Protty M, Morgan G, Pickering J, Delon C, Watkins J. Aspirin and cancer: biological mechanisms and clinical outcomes. Open Biol. 2022;12(9):220124.","journal-title":"Open Biol"},{"issue":"1","key":"1900_CR96","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s42490-021-00052-w","volume":"3","author":"R Saraf","year":"2021","unstructured":"Saraf R, Agah S, Datta A, Jiang X. Drug target ranking for glioblastoma multiforme. BMC Biomed Eng. 2021;3(1):7.","journal-title":"BMC Biomed Eng"},{"issue":"4","key":"1900_CR97","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3171\/2011.5.JNS113","volume":"115","author":"F Lan","year":"2011","unstructured":"Lan F, Yue X, Han L, Yuan X, Shi Z, Huang K, Yang Y, Zou J, Zhang J, Jiang T, et al. Antitumor effect of aspirin in glioblastoma cells by modulation of \u03b2-catenin\/T-cell factor-mediated transcriptional activity. J Neurosurg. 2011;115(4):780\u20138.","journal-title":"J Neurosurg"},{"issue":"9","key":"1900_CR98","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1007\/s12035-019-1513-6","volume":"56","author":"J Guenzle","year":"2019","unstructured":"Guenzle J, Garrelfs NWC, Goeldner JM, Weyerbrock A. Cyclooxygenase (COX) inhibition by acetyl salicylic acid (ASA) enhances antitumor effects of nitric oxide in glioblastoma in vitro. Mol Neurobiol. 2019;56(9):6046\u201355.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"1900_CR99","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1179\/016164103101201706","volume":"25","author":"R Amin","year":"2003","unstructured":"Amin R, Kamitani H, Sultana H, Taniura S, Islam A, Sho A, Ishibashi M, Eling TE, Watanabe T. Aspirin and indomethacin exhibit antiproliferative effects and induce apoptosis in T98G human glioblastoma cells. Neurol Res. 2003;25(4):370\u20136.","journal-title":"Neurol Res"},{"key":"1900_CR100","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/j.wneu.2018.08.080","volume":"120","author":"SE Navone","year":"2018","unstructured":"Navone SE, Guarnaccia L, Cordiglieri C, Cris\u00e0 FM, Caroli M, Locatelli M, Schisano L, Rampini P, Miozzo M, La Verde N, et al. Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib, impairing vascular endothelial growth factor-related signaling. World Neurosurg. 2018;120:e380\u201391.","journal-title":"World Neurosurg"},{"issue":"2","key":"1900_CR101","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/cns.12041","volume":"19","author":"ZD Shi","year":"2013","unstructured":"Shi ZD, Qian XM, Liu CY, Han L, Zhang KL, Chen LY, Zhang JX, Pu PY, Yuan XB, Kang CS. Aspirin-\/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of \u03b2-catenin transactivation. CNS Neurosci Ther. 2013;19(2):98\u2013108.","journal-title":"CNS Neurosci Ther"},{"issue":"12","key":"1900_CR102","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/aje\/kwh153","volume":"159","author":"NR Sivak-Sears","year":"2004","unstructured":"Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M. Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol. 2004;159(12):1131\u20139.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"1900_CR103","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/bjc.2013.87","volume":"108","author":"D Gaist","year":"2013","unstructured":"Gaist D, Garc\u00eda-Rodr\u00edguez LA, S\u00f8rensen HT, Hallas J, Friis S. Use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs and risk of glioma: a case-control study. Br J Cancer. 2013;108(5):1189\u201394.","journal-title":"Br J Cancer"},{"issue":"3","key":"1900_CR104","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1055-9965.EPI-18-0702","volume":"28","author":"ES Amirian","year":"2019","unstructured":"Amirian ES, Ostrom QT, Armstrong GN, Lai RK, Gu X, Jacobs DI, Jalali A, Claus EB, Barnholtz-Sloan JS, Il\u2019yasova D, et al. Aspirin, NSAIDs, and Glioma risk: original data from the Glioma international case-control study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2019;28(3):555\u201362.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1900_CR105","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ebiom.2019.06.048","volume":"45","author":"T Wang","year":"2019","unstructured":"Wang T, Fu X, Jin T, Zhang L, Liu B, Wu Y, Xu F, Wang X, Ye K, Zhang W, et al. Aspirin targets P4HA2 through inhibiting NF-\u03baB and LMCD1-AS1\/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine. 2019;45:168\u201380.","journal-title":"EBioMedicine"},{"issue":"1","key":"1900_CR106","doi-asserted-by":"publisher","first-page":"12054","DOI":"10.1038\/s41598-022-16398-7","volume":"12","author":"S Alipour","year":"2022","unstructured":"Alipour S, Khalighfard S, Khori V, Amiriani T, Tajaldini M, Dehghan M, Sadani S, Omranipour R, Vahabzadeh G, Eslami B, et al. Innovative targets of the lncRNA-miR-mRNA network in response to low-dose aspirin in breast cancer patients. Sci Rep. 2022;12(1):12054.","journal-title":"Sci Rep"},{"issue":"5","key":"1900_CR107","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.21037\/tcr-20-2248","volume":"10","author":"M Chen","year":"2021","unstructured":"Chen M, Wu L, Zhan H, Liu T, He Y. Aspirin-induced long non-coding RNA suppresses colon cancer growth. Transl Cancer Res. 2021;10(5):2055\u201369.","journal-title":"Transl Cancer Res"},{"issue":"10","key":"1900_CR108","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41419-023-06226-9","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Rokavec M, Huang Z, Hermeking H. Salicylate induces AMPK and inhibits c-MYC to activate a NRF2\/ARE\/miR-34a\/b\/c cascade resulting in suppression of colorectal cancer metastasis. Cell Death Dis. 2023;14(10):707.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1900_CR109","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3892\/ijo.2020.5165","volume":"58","author":"T Shi","year":"2021","unstructured":"Shi T, Gong J, Fujita K, Nishiyama N, Iwama H, Liu S, Nakahara M, Yoneyama H, Morishita A, Nonura T, et al. Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo. Int J Oncol. 2021;58(2):199\u2013210.","journal-title":"Int J Oncol"},{"issue":"2","key":"1900_CR110","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3892\/or.2020.7630","volume":"44","author":"T Shi","year":"2020","unstructured":"Shi T, Fujita K, Gong J, Nakahara M, Iwama H, Liu S, Yoneyama H, Morishita A, Nomura T, Tani J, et al. Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. Oncol Rep. 2020;44(2):457\u201368.","journal-title":"Oncol Rep"},{"issue":"8","key":"1900_CR111","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.21873\/anticanres.15900","volume":"42","author":"R Nakabayashi","year":"2022","unstructured":"Nakabayashi R, Fujihara S, Iwama H, Hamaya S, Mizuo T, Hirata M, Fujita K, Kono T, Namima D, Fujita N, et al. Effect of aspirin on G(0)\/G(1) cell cycle arrest and microRNA signatures in pancreatic adenocarcinoma cells. Anticancer Res. 2022;42(8):4037\u201348.","journal-title":"Anticancer Res"},{"issue":"6","key":"1900_CR112","doi-asserted-by":"publisher","first-page":"152379","DOI":"10.1016\/j.prp.2019.03.008","volume":"215","author":"J Chen","year":"2019","unstructured":"Chen J, Xu R, Xia J, Huang J, Su B, Wang S. Aspirin inhibits hypoxia-mediated lung cancer cell stemness and exosome function. Pathol Res Pract. 2019;215(6):152379.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"1900_CR113","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273\u201386.","journal-title":"Biostatistics"},{"key":"1900_CR114","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","volume":"68","author":"NT Issa","year":"2021","unstructured":"Issa NT, Stathias V, Sch\u00fcrer S, Dakshanamurthy S. Machine and deep learning approaches for cancer drug repurposing. Semin Cancer Biol. 2021;68:132\u201342.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1900_CR115","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):160.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1900_CR116","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tig.2022.10.004","volume":"39","author":"I Orsolic","year":"2023","unstructured":"Orsolic I, Carrier A, Esteller M. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet. 2023;39(1):74\u201388.","journal-title":"Trends Genet"},{"issue":"1","key":"1900_CR117","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","volume":"14","author":"J Tao","year":"2023","unstructured":"Tao J, Bauer DE, Chiarle R. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nat Commun. 2023;14(1):212.","journal-title":"Nat Commun"},{"issue":"1","key":"1900_CR118","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cmet.2022.11.001","volume":"35","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G. Meta-hallmarks of aging and cancer. Cell Metab. 2023;35(1):12\u201335.","journal-title":"Cell Metab"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01900-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01900-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01900-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:02:42Z","timestamp":1750510962000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01900-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01900-5","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"We grant our consent for the publication of this work, acknowledging that all authors have reviewed and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}